Bazzoli Andrea, Vance David J, Rudolph Michael J, Rong Yinghui, Angalakurthi Siva Krishna, Toth Ronald T, Middaugh C Russell, Volkin David B, Weis David D, Karanicolas John, Mantis Nicholas J
Center for Computational Biology, University of Kansas, Lawrence, Kansas, 66045.
Computational Chemical Biology Core, University of Kansas, Lawrence, Kansas, 66047.
Proteins. 2017 Nov;85(11):1994-2008. doi: 10.1002/prot.25353. Epub 2017 Aug 4.
In this report we investigated, within a group of closely related single domain camelid antibodies (V Hs), the relationship between binding affinity and neutralizing activity as it pertains to ricin, a fast-acting toxin and biothreat agent. The V1C7-like V Hs (V1C7, V2B9, V2E8, and V5C1) are similar in amino acid sequence, but differ in their binding affinities and toxin-neutralizing activities. Using the X-ray crystal structure of V1C7 in complex with ricin's enzymatic subunit (RTA) as a template, Rosetta-based homology modeling coupled with energetic decomposition led us to predict that a single pairwise interaction between Arg29 on V5C1 and Glu67 on RTA was responsible for the difference in ricin toxin binding affinity between V1C7, a weak neutralizer, and V5C1, a moderate neutralizer. This prediction was borne out experimentally: substitution of Arg for Gly at position 29 enhanced V1C7's binding affinity for ricin, whereas the reverse (ie, Gly for Arg at position 29) diminished V5C1's binding affinity by >10 fold. As expected, the V5C1 mutant was largely devoid of toxin-neutralizing activity (TNA). However, the TNA of the V1C7 mutant was not correspondingly improved, indicating that in the V1C7 family binding affinity alone does not account for differences in antibody function. V1C7 and V5C1, as well as their respective point mutants, recognized indistinguishable epitopes on RTA, at least at the level of sensitivity afforded by hydrogen-deuterium mass spectrometry. The results of this study have implications for engineering therapeutic antibodies because they demonstrate that even subtle differences in epitope specificity can account for important differences in antibody function.
在本报告中,我们在一组密切相关的单域骆驼科抗体(VHs)中,研究了与蓖麻毒素(一种速效毒素和生物威胁剂)相关的结合亲和力与中和活性之间的关系。V1C7样VHs(V1C7、V2B9、V2E8和V5C1)在氨基酸序列上相似,但结合亲和力和毒素中和活性不同。以V1C7与蓖麻毒素酶亚基(RTA)复合物的X射线晶体结构为模板,基于Rosetta的同源建模结合能量分解,使我们预测V5C1上的Arg29与RTA上的Glu67之间的单个成对相互作用是造成V1C7(一种弱中和剂)和V5C1(一种中等中和剂)之间蓖麻毒素结合亲和力差异的原因。这一预测在实验中得到了证实:在第29位用Arg取代Gly增强了V1C7对蓖麻毒素的结合亲和力,而相反的替换(即第29位用Gly取代Arg)使V5C1的结合亲和力降低了10倍以上。正如预期的那样,V5C1突变体基本上没有毒素中和活性(TNA)。然而,V1C7突变体的TNA并没有相应提高,这表明在V1C7家族中,仅结合亲和力并不能解释抗体功能的差异。V1C7和V5C1以及它们各自的点突变体在RTA上识别出难以区分的表位,至少在氢氘质谱提供的灵敏度水平上是如此。本研究结果对治疗性抗体的工程设计具有启示意义,因为它们表明即使表位特异性的细微差异也可能导致抗体功能的重要差异。